Patents Examined by Agnieszka Boesen
  • Adenovirus polynucleotides and polypeptides
    Patent number: 11414679
    Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 16, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia Ammendola, Stefania Capone, Stefano Colloca, Antonella Folgori, Rossella Merone
  • Methods for continuously inactivating a virus during manufacture of a protein
    Patent number: 11407981
    Abstract: Methods for continuously inactivating a virus during manufacture of a protein are provided. Steps include (1) combining, at a single predetermined volumetric ratio, a composition including the protein, and a composition including a virus-inactivation reagent, to obtain a treatment composition having a predetermined property for inactivation of a virus; (2) transferring the treatment composition to a treatment vessel; (3) incubating the treatment composition in the treatment vessel at predetermined conditions; and (4) subjecting the treatment composition to a post-treatment processing operation. The single predetermined volumetric ratio has been selected to ensure that the predetermined property of the treatment composition is maintained across a range of concentrations predicted for the protein in the composition including the protein.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: August 9, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Marcus Andre Fiadeiro, Jonathan Coffman, Robert Lee Fahrner, Jill Ann Kublbeck, Raquel Orozco, Jeffrey Richard Salm
  • Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
    Patent number: 11406705
    Abstract: The present disclosure provides methods, uses and compositions and kits for use in inducing an antibody immune response in a human subject. The methods and uses involve administering parenterally a low dose volume of a composition comprising an antigen comprising a B-cell epitope, an amphipathic compound, and a hydrophobic carrier, wherein the low dose volume of the composition is less than 100 ?l and induces an antibody immune response to the B-cell epitope in the human subject.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: August 9, 2022
    Assignee: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marc Mansour, Frederic Ors, Marianne Stanford, Leeladhar Sammatur, Rajkannan Rajagopalan, Lisa Diana MacDonald
  • Mumps virus as a potential oncolytic agent
    Patent number: 11401511
    Abstract: This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: August 2, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Mark J. Federspiel, Arun Ammayappan, Gennett Pike, Stephen James Russell
  • T-cell modulatory multimeric polypeptides and methods of use thereof
    Patent number: 11401314
    Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: August 2, 2022
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo Chaparro
  • Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
    Patent number: 11400150
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: August 2, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Government of the United States, as Represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Antibodies that potently neutralize hepatitis B virus and uses thereof
    Patent number: 11390664
    Abstract: The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and potently neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The invention also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: July 19, 2022
    Assignee: HUMABS BIOMED SA
    Inventor: Davide Corti
  • EHV with inactivated UL18 and/or UL8
    Patent number: 11384365
    Abstract: The present invention relates to the field of (vector) vaccines, and especially to novel EHV's having an inactivation of UL18 and/or UL8. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: July 12, 2022
    Inventors: Ramesh Koukuntla, Jana M. Larsen, Robert Barry Mandell, Luka N. Pelz, Eric Martin Vaughn
  • T-cell modulatory multimeric polypeptides and methods of use thereof
    Patent number: 11377478
    Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: July 5, 2022
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Targeting the cofilin pathway
    Patent number: 11377499
    Abstract: The present disclosure provides a method of restoring immune reconstitution, immune control of viremia, and one or more T cell functions in a subject infected with HIV. The method includes administering to the subject infected with HIV an agent that targets the cofilin pathway.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: July 5, 2022
    Assignee: George Mason University
    Inventor: Yuntao Wu
  • Non-covalent loading of plant picovirus particles
    Patent number: 11371025
    Abstract: A method of non-covalently loading a plant picornavirus is described. The method includes contacting a plant picornavirus in solution with a molar excess of a cargo molecule to load the plant picornavirus with the cargo molecule, and then purifying the loaded plant picornavirus. Examples of cargo molecules include imaging agents, antitumor agents, and antiviral agents. Loaded plant picornaviruses prepared in this manner can be used to delivering cargo molecule to cells.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: June 28, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole Steinmetz, Daniel Popkin
  • T-cell modulatory multimeric polypeptides and methods of use thereof
    Patent number: 11370821
    Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: June 28, 2022
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Vaccine compositions having improved stability and immunogenicity
    Patent number: 11364294
    Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: June 21, 2022
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
  • Humanized anti-claudin-1 antibodies and uses thereof
    Patent number: 11365251
    Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: June 21, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de Strasbourg
    Inventors: Thomas Baumert, Rajeevkumar Tawar
  • Antibody-mediated neutralization of chikungunya virus
    Patent number: 11345743
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: May 31, 2022
    Assignee: VANDERBILT UNIVERSITY
    Inventors: James E. Crowe, Jr., Scott A. Smith, Terence Dermody, Laurie Silva
  • Subject anti-HCV antibody detection assays employing NS3 capture peptides
    Patent number: 11340230
    Abstract: The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay. In other embodiments, methods are provided of detecting NS3-specific subject antibodies without the use of a reducing agent. In some embodiments, NS3-specific subject antibodies are detected with a ‘double shot’ of NS3 conjugate peptide (e.g., conjugate peptide added to a sample both before and after washing).
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: May 24, 2022
    Assignee: Abbott Laboratories
    Inventors: Anthony S. Muerhoff, John C. Prostko, Christopher C. Marohnic
  • Pretreatment method for rapid detection of HCV core antigen
    Patent number: 11327077
    Abstract: The present disclosure relates to a method for detecting a core polypeptide of a hepatitis C virus (HCV) in a sample from a subject with the steps of (a) contacting the sample with a surfactant comprising a cationic detergent; (b) contacting the sample with a binding compound; and (c) detecting a core polypeptide of the HCV in the sample; wherein step a) is immediately followed by step b). The present disclosure further relates to a method for pre-processing a sample from a subject for detection of an HCV core polypeptide, involving (a) contacting the sample with a surfactant comprising a cationic detergent and, optionally, with an agent inducing a pH shift, immediately followed by (b) contacting the sample with a binding compound. Moreover, the present disclosure further relates to uses, devices, and analytical systems related to aforesaid methods.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: May 10, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Barbara Upmeier, Toralf Zarnt, Manfred Ginter, Ralf Bollhagen
  • Delivery of RNA to trigger multiple immune pathways
    Patent number: 11324770
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: May 10, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Anti-dengue virus NS1 protein monoclonal antibodies
    Patent number: 11320433
    Abstract: The present invention provides matched antibody pairs for the specific detection of one or more of the four dengue virus serotypes in a biological sample that may contain one or more of such dengue virus serotypes. Each matched antibody pair is capable of detecting not more than one serotype of dengue virus NS1 protein that may be present in the sample and will not cross react with other serotypes that may be present in the sample. Multiple matched pairs may be used to detect one or more dengue virus serotypes that may be present in a sample. Such matched pair antibodies, facilitate the development of confirmatory in vitro diagnostic tests such as sandwich immunoassays, that detect and distinguish the presence of one or more dengue virus serotypes in a biological sample, preferably a sample derived from human subject.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 3, 2022
    Assignees: Massachusetts Institute of Technology, The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Irene Bosch, Kimberly Hamad-Schifferli, Jose Gomez-Marquez, Helena dePuig Guixe, Lee Gehrke
  • Development of agonist epitopes of the human papillomavirus
    Patent number: 11311613
    Abstract: The invention provides HPV agonist epitopes, which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of HPV infection and/or cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: April 26, 2022
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang